Seeking Alpha

SA Pro author Stephen Simpson's bullish take on Sanofi (SNY) touches on the blockbuster...

SA Pro author Stephen Simpson's bullish take on Sanofi (SNY) touches on the blockbuster potential of the company's MS drug, Lemtrada. A commenter points out Contingent Value Rights on Lemtrada allow investors a pure-play bet on the drug's success. The possible undervaluation of the CVR is covered in an interesting article by SA Pro author Chris DeMuth (along with great comment thread).
From other sites
Comments (1)
  • Chris DeMuth Jr.
    , contributor
    Comments (5654) | Send Message
     
    SNY has been active at repurchasing GCVRZ as they head into the FDA decision. It will be intesting to see if and when they will be able to buy back more before that milestone.
    17 Feb 2013, 10:29 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs